These findings in human SSTs and in vitro models provide evidence to suggest that the oncogenic behavior of SSTs can at least in part be explained by activation of the SHH pathway, and the potential of GLI2 rearrangements to serve as a marker for these uncommon ovarian neoplasms. This evidence concerns the gene GLI2 and ovarian neoplasm.